Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 4/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 7/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | HTR7 | P34969 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28135156 | 0.81 | MAPT (0.78) | ALDH1A1NPC1RAB9AMAPTLMNA | |
| SCHEMBL22014821 | 0.80 | KDM4E (0.50) | ALDH1A1NPC1RAB9AMAPTLMNA | |
| SCHEMBL8245954 | 0.79 | MAPT (0.70) | ALDH1A1NPC1RAB9AMAPTLMNA | |
| SCHEMBL24209212 | 0.78 | MAPT (0.50) | ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL22014826 | 0.75 | CYP2D6 (0.62) | HTR1AHTR7KMT2A | |
| SCHEMBL30528252 | 0.75 | MAPT (0.86) | ALDH1A1NPC1RAB9AMAPTLMNA | |
| SCHEMBL24208969 | 0.75 | POLB (0.48) | ALDH1A1NPC1RAB9AMAPTLMNA | |
| SCHEMBL22014791 | 0.74 | ALDH1A1 (0.35) | ALDH1A1NPC1RAB9ALMNANPSR1 | |
| SCHEMBL24208950 | 0.74 | CYP1A2 (0.39) | ALDH1A1NPC1RAB9AMAPTNPSR1 | |
| SCHEMBL7840682 | 0.74 | MAPT (0.72) | ALDH1A1NPC1RAB9AMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017516-A1 | LOX INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2022-01-20 | — | — | US | disclosed |
| WO-2020099886-A1 | LOX INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017516-A1 | LOX INHIBITORS | LOXL1, LOX, LOXL2 | ALDH1A1 122/4885NPC1 1690/4885RAB9A 3337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.